A phase 3b trial found that Otsuka's centanafadine significantly improved both ADHD symptoms and anxiety symptoms in adults with ADHD and comorbid anxiety, with effects emerging as early as week 1 and holding through 8 weeks, as the drug awaits an FDA decision expected July 24, 2026.
In this interview, Marc Elia argues that monoclonal antibodies like VYD2311 offer a fundamentally different approach to COVID-19 prevention than vaccines, delivering protective antibodies directly rather than triggering an immune response, which he says could improve tolerability.
GLP-1 receptor agonists can help reduce inflammation and improve blood vessel function in patients with peripheral artery disease.
United Healthcare, Express Scripts, Cigna, Optum Rx and TRICARE offer Neffy without restriction. Neffy is an epinephrine nasal spray available for anaphylaxis.
If approved to treat patients with mantle cell lymphoma, Brukinsa plus rituximab would be the first chemotherapy-free regimen for newly diagnosed patients.
There are lots of clues. But far more research is needed to find out whether metabolic dysfunction-associated steatotic liver disease (MASLD) plays a causative role in breast cancer.
The approval was supported by the pivotal phase 3 THRIVE and THRIVE-2 trials, which evaluated veligrotug in active and chronic TED.
Healthcare leaders rank improving the patient experience ahead of digital transformation and cost reduction, and it can't be done without a trusted identity foundation.
Rather than considering prior authorization metrics separately, a Friction Index combines,
The approach of pairing an ecological framework with AI methods offers a new way to identify where diabetes risk concentrates.
Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.
Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.
A new meta-analysis suggests that combining immunotherapy and chemotherapy might be the best choice for treating advanced non-small cell lung cancer.
Addressing social determinants of health is now a strategic pillar of organizational planning, compliance, and long-term sustainability.
Results from the DAPHNe trial point to ctDNA as having a role in guiding treatment, but the researchers and a commentator say more research needs to be done before determining exactly what it is.
Age, skin phototype, and personal history of skin cancer are easily captured data elements that could form the basis of a practical, risk-stratified approach to surveillance.
The two conditions can have similar manifestations but differ in prognosis and treatment, which makes an accurate, early diagnosis important.
Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.
Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics.
If prospective studies of clinical outcomes confirm the findings, one near-term application of the research might be using automated analysis of speech samples to monitor patients with schizophrenia.
Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.
In this discussion, Jorge Nieva, M.D., professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center, explores how pesticide exposure from otherwise “healthy” diets may help explain the rise of early-onset lung cancer in non-smokers.
The healthcare industry succeeded in making behavioral healthcare more accessible, argues Machinify's Lisa Pincher. Now, it must build the infrastructure to support that care responsibly.
Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.
The Lown Institute’s annual social responsibility index gave the Ohio and Philadelphia systems the highest marks.
Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient’s pain.
If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.
The findings add to the evidence that targeted therapies can improve outcomes in early-stage, oncogene-driven lung cancers, say the study's authors.
An electronic health record–based diabetes risk tool helped primary care teams target prevention and reduce progression to type 2 diabetes in prediabetes patients.
David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company’s merger and how the combined company is positioned for the PBM market of the future.
